CYP2B6*6 and Ketamine Metabolism
1271
Authorship Contributions
Participated in research design: Li, Coller, Hutchinson, Klein, Zanger,
Somogyi.
Conducted experiments: Li.
Contributed new reagents or analytic tools: Coller, Klein, Zanger, Stanley,
Abell, Somogyi.
Performed data analysis: Li, Coller, Somogyi.
Wrote or contributed to the writing of the manuscript: Li, Coller, Hutchinson,
Klein, Zanger, Stanley, Abell, Somogyi.
References
Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, Ishii I, Ishikawa T,
and Kitada M (2011) Q172H replacement overcomes effects on the metabolism of cyclo-
phosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 39:
2045–2048.
Chong C, Schug SA, Page-Sharp M, Jenkins B, and Ilett KF (2009) Development of a sublingual/
oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way
randomized, crossover study. Clin Drug Investig 29:317–324.
Dale O, Somogyi AA, Li Y, Sullivan T, and Shavit Y (2012) Does intraoperative ketamine
attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis.
Anesth Analg 115:934–943.
Ebert B, Mikkelsen S, Thorkildsen C, and Borgbjerg FM (1997) Norketamine, the main me-
tabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and
spinal cord. Eur J Pharmacol 333:99–104.
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T,
Marzolini C, and Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system
side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400.
Hijazi Y and Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms
to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:
853–858.
Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, and Zanger UM
(2008) Aberrant splicing caused by single nucleotide polymorphism c.516G.T [Q172H],
a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in
liver. J Pharmacol Exp Ther 325:284–292.
Hong SC and Davisson JN (1982) Stereochemical studies of demethylated ketamine enantiomers.
J Pharm Sci 71:912–914.
Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004)
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration
of phenotypic null alleles. J Pharmacol Exp Ther 311:34–43.
Locuson CW, Wienkers LC, Jones JP, and Tracy TS (2007) CYP2C9 protein interactions
with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos 35:
1174–1181.
Mathisen LC, Skjelbred P, Skoglund LA, and Oye I (1995) Effect of ketamine, an NMDA
receptor inhibitor, in acute and chronic orofacial pain. Pain 61:215–220.
Meyer S, Aliani S, Graf N, and Gottschling S (2004) Inter- and intraindividual variability in
ketamine dosage in repetitive invasive procedures in children with malignancies. Pediatr
Hematol Oncol 21:161–166.
Mössner LD, Schmitz A, Theurillat R, Thormann W, and Mevissen M (2011) Inhibition of
cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and
specific cytochrome P450 enzymes from horses, dogs, and humans. Am J Vet Res 72:
1505–1513.
Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, and Minami
H
(2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/
Fig. 6. Effect of CYP2B6 and CYP3A4 inhibitors on norketamine formation from
both low and high ketamine concentrations in HLMs with CYP2B6*1/*1 (n = 4),
CYP2B6*1/*6 (n = 4), and CYP2B6*6/*6 (n = 3) genotypes. Low substrate
concentrations were equivalent to the relative Km1 values; high substrate
concentrations were equivalent to the relative Km2 values. MAB-3A, monoclonal
antibody against CYP3A; MAB-2B6, monoclonal antibody against CYP2B6;
TAO, troleandomycin. Results represent the mean 6 S.D. #Significant inhibition
P , 0.05; **Significant gene-dose effect on inhibitory effects among three
genotype groups, P , 0.01.
pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet
Genomics 17:431–445.
Omura T and Sato R (1964) The Carbon monoxide-binding pigment of liver microsomes. J Biol
Chem 239:2370–2378.
Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM,
Chandler CM, Boily N, Crespi CL, and Stresser DM (2009) Validation of cytochrome P450
time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay
design. Xenobiotica 39:99–112.
Perret A and Pompon D (1998) Electron shuttle between membrane-bound cytochrome P450 3A4
and b5 rules uncoupling mechanisms. Biochemistry 37:11412–11424.
Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, and Thormann W (2010)
Enantioselective capillary electrophoresis for identification and characterization of human
cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr
A 1217:7942–7948.
Skolnick P, Popik P, and Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends
Pharmacol Sci 30:563–569.
a CYP2B6 genetic polymorphism on in vitro ketamine N-demeth-
ylation. Our data also show that CYP2B6 but not CYP3A4 is the
major isoform responsible for the human liver microsomal ketamine
N-demethylation at clinically relevant concentrations. Nevertheless,
the role CYP3A4 increases as ketamine concentration increases. In ad-
dition, the ketamine metabolism to norketamine mediated by CYP2B6
and CYP3A4 was not stereoselective.
Steiner K, Gangkofner S, and Grunenwald JM (2000), inventors, Goedecke Aktiengesellschaft
and Cu Chemie Uetikon GmbH, assignees. Racemic separation of ketamine. U.S. patent
6040479A. 2000 Mar 21.
Subramaniam K, Subramaniam B, and Steinbrook RA (2004) Ketamine as adjuvant analgesic to
opioids: a quantitative and qualitative systematic review. Anesth Analg 99:482–495 table of
contents.
Turpeinen M and Zanger UM (2012) Cytochrome P450 2B6: function, genetics, and clinical
relevance. Drug Metabol Drug Interact 27:185–197.
Weiberth FJ and Hall SS (1987) Copper(I)-activated addition of Grignard reagents to nitriles.
Synthesis of ketimines, ketones, and amines. J Org Chem 52:3901–3904.
White PF, Ham J, Way WL, and Trevor AJ (1980) Pharmacology of ketamine isomers in surgical
patients. Anesthesiology 52:231–239.
Acknowledgments
White PF, Johnston RR, and Pudwill CR (1975) Interaction of ketamine and halothane in rats.
Anesthesiology 42:179–186.
The authors thank Joel Colvill for assistance with HPLC assay; Dr. Daniel
Barratt for help in genotyping assays; and Dr. Benjamin Lewis for help in
carbon monoxide difference spectrum assay.
White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, and Trevor AJ (1985) Compara-
tive pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:
197–203.